Citations

Clear

6274 citation(s) found for "To, Andrew".

The gain of function SCN1A disorder spectrum: novel epilepsy phenotypes and therapeutic implications
Brunklaus, Andreas , Brünger, Tobias , Feng, Tony, Lehikoinen, Anni , Panagiotakaki, Eleni , Vințan, Mihaela Adela , Symonds, Joseph D. , Andrew, James E., Delima, Sarah , Gallois, Julie, Hanrahan, Donncha, Macleod, Stewart, Marjanović, Dragan , McTague, Amy , Nuñez-Enamorado, Noemi, Pérez‐Palma, Eduardo , Perry, Μ. Scott , Pysden, Karen, Russ-Hall, Sophie , Scheffer, Ingrid E. , Sully, Krystal , Syrbe, Steffen , Vaher, Ulvi , Velayutham, Murugan, Vogt, Julie , Weiss, Shelly K. , Zuberi, Sameer M. , Lal, Dennis , Møller, Rikke S. , Mantegazza, Massimo , Symonds, Joseph , Zuberi, Sameer M , Mantegazza, Massimo , Brunklaus, Andreas , Scheffer, Ingrid E , Møller, Rikke S , Fons, Carmen , Andrew, James, Arzimanoglou, Alexis , Lesca, Gaëtan , Núñez‐Enamorado, Noemí , Wirrell, Elaine , Cestèle, Sandrine

Mayo Clinic

Brain | June 13, 2022 | Volume: 145 | Issue: 11 | Pages: 3816-3831

10.1093/brain/awac210 | PMID 35696452 Get It

Abstract Brain voltage-gated sodium channel NaV1.1 (SCN1A) loss-of-function variants cause the severe epilepsy Dravet syndrome, as well as milder phenotypes associated with genetic epilepsy with febrile seizures plus. Gain of function SCN1A variants are associated with familial hemiplegic migraine type 3. Novel SCN1A-related phenotypes have been described including early infantile developmental and epileptic encephalopathy with movement disorder, and more recently neonatal presentations with arthrogryposis. Here we describe the clinical, genetic and functional evaluation of affected individuals. Thirty-five patients were ascertained via an international collaborative network using a structured clinical questionnaire and from the literature. We performed whole-cell voltage-clamp electrophysiological recordings comparing sodium channels containing wild-type versus variant NaV1.1 subunits. Findings were related to Dravet syndrome and familial hemiplegic migraine type 3 variants. We identified three distinct clinical presentations differing by age at onset and presence of arthrogryposis and/or movement disorder. The most severely affected infants (n = 13) presented with congenital arthrogryposis, neonatal onset epilepsy in the first 3 days of life, tonic seizures and apnoeas, accompanied by a significant movement disorder and profound intellectual disability. Twenty-one patients presented later, between 2 weeks and 3 months of age, with a severe early infantile developmental and epileptic encephalopathy and a movement disorder. One patient presented after 3 months with developmental and epileptic encephalopathy only. Associated SCN1A variants cluster in regions of channel inactivation associated with gain of function, different to Dravet syndrome variants (odds ratio = 17.8; confidence interval = 5.4–69.3; P = 1.3 × 10−7). Functional studies of both epilepsy and familial hemiplegic migraine type 3 variants reveal alterations of gating properties in keeping with neuronal hyperexcitability. While epilepsy variants result in a moderate increase in action current amplitude consistent with mild gain of function, familial hemiplegic migraine type 3 variants induce a larger effect on gating properties, in particular the increase of persistent current, resulting in a large increase of action current amplitude, consistent with stronger gain of function. Clinically, 13 out of 16 (81%) gain of function variants were associated with a reduction in seizures in response to sodium channel blocker treatment (carbamazepine, oxcarbazepine, phenytoin, lamotrigine or lacosamide) without evidence of symptom exacerbation. Our study expands the spectrum of gain of function SCN1A-related epilepsy phenotypes, defines key clinical features, provides novel insights into the underlying disease mechanisms between SCN1A-related epilepsy and familial hemiplegic migraine type 3, and identifies sodium channel blockers as potentially efficacious therapies. Gain of function disease should be considered in early onset epilepsies with a pathogenic SCN1A variant and non-Dravet syndrome phenotype.
Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non–Small Cell Lung Carcinoma
Burke, Louise , Flieder, Douglas B. , Guinee, Donald G., Brambilla, E., Freedman, Andrew N. , Bennett, William P., Jones, Raymond T., Borkowski, Andrew , Caporaso, Neil A., Fleming, Marian V., Trastek, Victor F., Pairolero, Peter C., Tazelaar, Henry D. , Midthun, David E. , Jett, James R., Harris, Curtis C. , Tazelaar, Henry D. , Liotta, Lance A. , Travis, William D.

Mayo Clinic

Clinical Cancer Research | June 11, 2022 | Volume: 11 | Issue: 1 | Pages: 232-241

10.1158/1078-0432.232.11.1 Get It

Abstract Purpose: Many studies have highlighted the aberrant expression and prognostic significance of individual proteins in either the Rb (particularly cyclin D1, p16INK4A, and pRb) or the p53 (p53 and p21Waf1) pathways in non–small cell lung cancer. We hypothesize that cumulative abnormalities within each and between these pathways would have significant prognostic potential regarding survival. Experimental Design: Our study population consisted of 106 consecutive surgically resected cases of predominantly early-stage non–small cell lung cancer from the National Cancer Institute-Mayo Clinic series, and assessment of proteins involved both immunohistochemical (cyclin D1, p21Waf1, pRb, p16INK4A, and p53) and mutational analysis (p53) in relationship to staging and survival. Results: Cyclin D1 overexpression was noted in 48% of the tumors, p16INK4A negative in 53%, pRb negative in 17%, p53 immunopositive in 50%, p53 mutation frequency in 48%, and p21Waf1 overexpression in 47%, none with prognostic significance. Cyclin D1 overexpression in pRb-negative tumors revealed a significantly worse prognosis with a mean survival of 2.3 years (P = 0.004). A simultaneous p53 mutation dramatically reduced the mean survival time to 0.9 years (P = 0.007). Cyclin D1 overexpression with either a p53 mutation or a p53 overexpression was also associated with a significantly poorer prognosis (P = 0.0033 and 0.0063, respectively). Conclusions: Some cumulative abnormalities in the Rb and p53 pathways (e.g., cyclin D1 overexpression and p53 mutations) significantly cooperate to predict a poor prognosis; however, the complexity of the cell cycle protein interaction in any given tumor warrants caution in interpreting survival results when specific protein abnormalities are taken in isolation.
Glycogen Synthase Kinase-3 Inhibition Sensitizes Pancreatic Cancer Cells to Chemotherapy by Abrogating the TopBP1/ATR-Mediated DNA Damage Response
Madamsetty, Vijay Sagar , Kiers, Spencer, Alekhina, Olga, Ugolkov, Andrey , Dubé, John J. , Zhang, Yu, Zhang, Jin‐San , Wang, Enfeng , Dutta, Shamit K., Schmitt, Daniel M. , Kozikowski, Alan P. , Mazar, Andrew P. , Billadeau, Daniel D. , Alekhina, Olga , Dube, John, Zhang, Jin-San , Schmitt, Daniel M , Giles, Francis Joseph , Billadeau, Daniel D , Madamsetty, Vijay S , Ding, Li , Dube, John, Mukhopadhyay, Debabrata

Mayo Clinic

Clinical Cancer Research | June 11, 2022 | Volume: 25 | Issue: 21 | Pages: 6452-6462

10.1158/1078-0432.ccr-19-0799 | PMID 31533931 Get It

Abstract Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a predominantly fatal common malignancy with inadequate treatment options. Glycogen synthase kinase 3β (GSK-3β) is an emerging target in human malignancies including PDAC. Experimental Design: Pancreatic cancer cell lines and patient-derived xenografts were treated with a novel GSK-3 inhibitor 9-ING-41 alone or in combination with chemotherapy. Activation of the DNA damage response pathway and S-phase arrest induced by gemcitabine were assessed in pancreatic tumor cells with pharmacologic inhibition or siRNA depletion of GSK-3 kinases by immunoblotting, flow cytometry, and immunofluorescence. Results: 9-ING-41 treatment significantly increased pancreatic tumor cell killing when combined with chemotherapy. Inhibition of GSK-3 by 9-ING-41 prevented gemcitabine-induced S-phase arrest suggesting an impact on the ATR-mediated DNA damage response. Both 9-ING-41 and siRNA depletion of GSK-3 kinases impaired the activation of ATR leading to the phosphorylation and activation of Chk1. Mechanistically, depletion or knockdown of GSK-3 kinases resulted in the degradation of the ATR-interacting protein TopBP1, thus limiting the activation of ATR in response to single-strand DNA damage. Conclusions: These data identify a previously unknown role for GSK-3 kinases in the regulation of the TopBP1/ATR/Chk1 DNA damage response pathway. The data also support the inclusion of patients with PDAC in clinical studies of 9-ING-41 alone and in combination with gemcitabine.
Immunomodulatory effect of different statin regimens on regulatory T-cells among patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials
Greca, Elona , Kacimi, Salah Eddine Oussama , Wireko, A A, Toufik, A, Poudel, Sujan , Prendi, B, Michel, George , Michel, J, Awuah, Wireko Andrew , Ghozy, Sherief , Toufik, A, Michel, J

Mayo Clinic

Cardiovascular Research | June 10, 2022 | Volume: 118 | Issue: Supplement_1 | Pages: No page available

10.1093/cvr/cvac066.148 Get It

Abstract Funding Acknowledgements Type of funding sources: None. Immunomodulatory effect of different statin regimens on regulatory T-cells among patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials Introduction In patients with acute coronary syndrome (ACS), studies suggest that statin therapy, besides its role in reducing the progression of atherosclerosis through its pharmacological effect, plays a pivotal role in controlling the pathogenesis of ACS through the anti-inflammatory effects of suppressor regulatory T cells (Tregs). Purpose We conducted a network meta-analysis (NMA) to determine the effects of low-dose conventional statin therapy (CST) (20 mg/day or less) and high-dose intensive statin therapy (IST) (40 mg/day or more) on the frequency of Tregs and their associated cytokines (IFN-γ, IL-10, TGF-β), compared to placebo. Methods The PubMed, Cochrane Library, and EMBASE databases were searched for randomized clinical trials (RCTs) to identify relevant articles published until June 2021. We pooled data extracted from the included studies using the standardized mean difference (SMD). A random-effects model was used to conduct this NMA. Heterogeneity was evaluated using Cochran's Q- and the I2-test. GRADE(Grading of Recommendations, Assessment, Development and Evaluations) was used to assess the study's quality. Data analysis was conducted using R software. Results A total of 505 patients were enrolled in the 5 RCTs. The NMA indicated a significant increase in Treg frequency in the CST group compared with the control group (SMD 1.77; 95% CI: 0.77 – 2.76; P-value = 0.0005) and a larger increase in the Treg frequency associated with the IST group compared with the control group (SMD 2.12; 95% CI: 1.15 – 3.10; P-value < 0.0001). However, there was significant heterogeneity and inconsistency among the included studies (τ2 = 0.6096; τ = 0.7808; I2 = 91.2% [80.5%; 96.0%]). When compared to the placebo, both CST and IST increased levels of secreted IL-10 (SMD 2.69; 95% CI: 2.07 – 3.31; P-value < 0.0001 and (SMD 2.14; 95% CI: 1.76 – 2.52; P-value < 0.0001), respectively. In comparison to the control group, CST was associated with increased levels of TGF-β (SMD 3.83; 95% CI: 0.63 – 7.0; P-value = 0.0189). This association was not seen in the IST group. IFN-γ levels decreased significantly in both the IST and CST groups (SMD -1.52; 95% CI: -1.94 – -1.10; P-value < 0.0001) and (SMD -2.34; 95% CI: -2.73 – -1.95; P-value < 0.0001) respectively. Conclusions Our study suggests that both high and low dose statin groups showed increased Treg frequency compared to the placebo group. IST showed larger benefits. Statin therapy also increased IL-10 and TGF-β cytokine levels and decreased IFN-γ levels. Therefore, statins have the potential to be the main treatment to reduce the incidence of cardiovascular events and improve cardiac function in patients with ACS through immunomodulatory effect on Treg.
Focal Nodular Hyperplasia and Focal Nodular Hyperplasia–like Lesions
LeGout, Jordan D. , Bolan, Candice W. , Bowman, Andrew W. , Caserta, Melanie P. , Chen, Frank K. , Cox, Kelly , Sanyal, Rupan , Toskich, Beau B. , Lewis, Jason T., Alexander, Lauren F. , Bowman, Andrew W , Alexander, Lauren F , Toskich, Beau , Lewis, Jason T.

Mayo Clinic

RadioGraphics | June 10, 2022 | Volume: 42 | Issue: 4 | Pages: 1043-1061

10.1148/rg.210156 | PMID 35687520 Get It

Rates of Response to Atogepant for Migraine Prophylaxis Among Adults
Blumenfeld, Andrew , McAllister, Peter , Lu, Kaifeng , Dabruzzo, Brett , Miceli, Rosa, Severt, Lawrence, Finnegan, Michelle , Trugman, Joel M. , Lipton, Richard B. , Pozo‐Rosich, Patricia , Dodick, David W. , Li, Ye

Mayo Clinic

JAMA Network Open | June 8, 2022 | Volume: 5 | Issue: 6 | Pages: e2215499

10.1001/jamanetworkopen.2022.15499 | PMID 35675076 Get It

Durability analysis of the highly effective BNT162b2 vaccine against COVID-19
Puranik, Arjun, Lenehan, Patrick J. , O’Horo, John C. , Pawlowski, Colin , Niesen, Michiel J.M. , Virk, Abinash , Swift, Melanie D. , Kremers, Walter K. , Gordon, Joel , Geyer, Holly L. , Speicher, Leigh L. , Gordon, Joel E, Speicher, Leigh Lewis, Soundararajan, Venky , O'Horo, John C , Swift, Melanie D , Lenehan, Patrick J , Kremers, Walter K , Venkatakrishnan, A J , Soundararajan, Venky , Badley, Andrew D.

Mayo Clinic

PNAS Nexus | June 8, 2022 | Volume: 1 | Issue: 3 | Pages: No page available

10.1093/pnasnexus/pgac082 | PMID 35832867 Get It

Abstract COVID-19 vaccines are effective, but breakthrough infections have been increasingly reported. We conducted a test-negative case-control study to assess the durability of protection after full vaccination with BNT162b2 against polymerase chain reaction (PCR)-confirmed symptomatic SARS-CoV-2 infection, in a national medical practice from January 2021 through January 2022. We fit conditional logistic regression (CLR) models stratified on residential county and calendar time of testing to assess the association between time elapsed since vaccination and the odds of symptomatic infection or non-COVID-19 hospitalization (negative control), adjusted for several covariates. There were 5,985 symptomatic individuals with a positive test after full vaccination with BNT162b2 (cases) and 32,728 negative tests contributed by 27,753 symptomatic individuals after full vaccination (controls). The adjusted odds of symptomatic infection were higher 250 days after full vaccination versus at the date of full vaccination (Odds Ratio [OR]: 3.62, 95% CI: 2.52 to 5.20). The odds of infection were still lower 285 days after the first BNT162b2 dose as compared to 4 days after the first dose (OR: 0.50, 95% CI: 0.37 to 0.67), when immune protection approximates the unvaccinated status. Low rates of COVID-19 associated hospitalization or death in this cohort precluded analyses of these severe outcomes. The odds of non-COVID-19 associated hospitalization (negative control) decreased with time since vaccination, suggesting a possible underestimation of waning protection by this approach due to confounding factors. In summary, BNT162b2 strongly protected against symptomatic SARS-CoV-2 infection for at least 8 months after full vaccination, but the degree of protection waned significantly over this period.
Data Analytics of Electronic Health Records to Enhance Care of Coronary Artery Disease in Younger Women with Avoiding Possible Delay in Treatment
Panahiazar, Maryam , Bishara, Andrew , Chern, Yorick, Latif, Omar, Hadley, Dexter , Beygui, Ramin E. , Latif, Omar S, Alizadehsani, Roohallah

Mayo Clinic

Studies in Health Technology and Informatics | June 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3233/shti220277 | PMID 35673215 Get It

Early detection plays a key role to enhance the outcome for Coronary Artery Disease. We utilized a big data analytics platform on ∼32,000 patients to trace patients from the first encounter to CAD treatment. There are significant gender-based differences in patients younger than 60 from the time of the first encounter to Coronary Artery Bypass Grafting with a p-value=0.03. This recognition makes significant changes in outcome by avoiding delay in treatment.
The Implication of Latent Information Quality to the Reproducibility of Secondary Use of Electronic Health Records
Pagali, Sandeep R. , Zong, Nansu , Sohn, Sunghwan , Fan, Jungwei , St Sauver, Jennifer, Pagali, Sandeep , Fan, Jungwei , Fu, Sunyang , Wen, Andrew , Sauver, Jennifer L. St. , Liu, Hongfang

Mayo Clinic

Studies in Health Technology and Informatics | June 7, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.3233/shti220055 | PMID 35672994 Get It

Reproducibility is an important quality criterion for the secondary use of electronic health records (EHRs). However, multiple barriers to reproducibility are embedded in the heterogeneous EHR environment. These barriers include complex processes for collecting and organizing EHR data and dynamic multi-level interactions occurring during information use (e.g., inter-personal, inter-system, and cross-institutional). To ensure reproducible use of EHRs, we investigated four information quality dimensions and examine the implications for reproducibility based on a real-world EHR study. Four types of IQ measurements suggested that barriers to reproducibility occurred for all stages of secondary use of EHR data. We discussed our recommendations and emphasized the importance of promoting transparent, high-throughput, and accessible data infrastructures and implementation best practices (e.g., data quality assessment, reporting standard).